VIDEOS

2.5 years of possibility

0:40

2.5 years of possibility
Embark Now to Gain More?

1:15

Embark Now to Gain More
Expert Prof Subodh Verma VDO 3-Take the Lead, Act

3:49

Expert Prof Subodh Verma VDO 3-Take the Lead, Act
Are your T2D patients on the right DPP4i dose?

00:48

Are your T2D patients on the right DPP4i dose?
DPP4i - Proven efficacy with no dose reduction

00:38

DPP4i - Proven efficacy with no dose reduction
DPP4i – What efficacy to expect?

00:27

DPP4i – What efficacy to expect?
Efficacy, Safety, Simplicity all in one DPP4i

00:54

Efficacy, Safety, Simplicity all in one DPP4i
JENTADUETO® dosing information

01:22

JENTADUETO® dosing information
Renally impaired patients - Are they on the right dose?

00:38

Renally impaired patients - Are they on the right dose?
Restricting TRAJENTA® to only renally impaired patients

00:21

Restricting TRAJENTA® to only renally impaired patients
Causes for stroke and its Diagnosis

02:22

Causes for stroke and its Diagnosis
How to recognize Stroke?

02:10

How to recognize Stroke?
Treatment

01:18

Treatment
Actilyse Dosing

03:15

Actilyse Dosing
High Residual CV Risk

03:20

High Residual CV Risk
Effect On Honeycombing Efficacy

02:44

Effect On Honeycombing Efficacy
Efficacy with Concomitant Emphysema

03:17

Efficacy with Concomitant Emphysema
Expert Opinion

00:57

Expert Opinion
Mechanism of Action

03:20

Mechanism of Action
Survival Analysis

05:58

Survival Analysis
Patients Subgroup Analysis

09:33

Patients Subgroup Analysis
Why was the data of the INPULSIS<sup>®</sup> and TOMORROW trials pooled?

02:03

Why was the data of the INPULSIS® and TOMORROW trials pooled?
EMPA-REG OUTCOME Results - Video

03:20

EMPA-REG OUTCOME Results - Video
Value Proposition

03:20

Value Proposition
Are patients with type 2 diabetes at elevated CV risk?

02:23

Are patients with type 2 diabetes at elevated CV risk?
Is Jardiance a medication for both endocrinologists and cardiologists?

02:23

Is Jardiance a medication for both endocrinologists and cardiologists?
Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?

01:52

Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it?
Do you use Empagliflozin for CV risk reduction in T2DM patients?

06:36

Do you use Empagliflozin for CV risk reduction in T2DM patients?
Should we move beyond glucose lowering as the main treatment goal?

02:46

Should we move beyond glucose lowering as the main treatment goal?
What are your thoughts on the 35% relative risk reduction?

01:42

What are your thoughts on the 35% relative risk reduction?
What are your views on the 38% relative risk reduction in CV death with Jardiance?

02:22

What are your views on the 38% relative risk reduction in CV death with Jardiance?
What does lowering the risk of CV death? - John Wilding

01:56

What does lowering the risk of CV death? - John Wilding
What does lowering the risk of CV death? - Lars Ryden

01:51

What does lowering the risk of CV death? - Lars Ryden
What were the key findings from EMPA-REG OUTCOME?

02:29

What were the key findings from EMPA-REG OUTCOME?
Load more

Clinical studies

Carmelina Cardiovascular Results - No HHF

icoPDF

Carmelina Cardiovascular Results - No HHF
Carmelina Cardiovascular Results

icoPDF

Carmelina Cardiovascular Results
Carmelina Kidney Results - Lower Risk Of Albuminurea

icoPDF

Carmelina Kidney Results - Lower Risk Of Albuminurea
Carmelina Kidney Results

icoPDF

Carmelina Kidney Results
Safety

icoPDF

Safety
Trajenta Simplicity of Dosing

icoPDF

Trajenta Simplicity of Dosing
Trajenta Simplicity

icoPDF

Trajenta Simplicity
Trajenta Efficacy

icoPDF

Trajenta Efficacy vs
Trajenta Efficacy Regardless of Age

icoPDF

Trajenta Efficacy Regardless of Age
Trajenta Efficacy With Same Dose In Severe Renal Impairment

icoPDF

Trajenta Efficacy With Same Dose In Severe Renal Impairment
Trajenta Efficacy With Same Dose Regardless of Kidney Function

icoPDF

Trajenta Efficacy With Same Dose Regardless of Kidney Function
Carmelina Study Design

icoPDF

Carmelina Study Design
Carmelina Study Inclusion Criteria

icoPDF

Carmelina Study Inclusion Criteria
Carmelina Trial Overview

icoPDF

Carmelina Trial Overview
Trajenta Efficacy up to 104 Weeks vs Glimepride

icoPDF

Trajenta Efficacy up to 104 Weeks vs Glimepride
Trajenta Efficacy Added To Metformin

icoPDF

Trajenta Efficacy Added To Metformin
Trajenta Efficacy Regardless of BMI

icoPDF

Trajenta Efficacy Regardless of BMI
Trajenta Efficacy vs Pioglitazone

icoPDF

Trajenta Efficacy vs Pioglitazone
Actilyse Dosing 2

icoPDF

Actilyse Dosing 2
Symptoms of Stroke

icoPDF

Symptoms of Stroke
Treatment of Stroke

icoPDF

Treatment of Stroke
EMPA-REG OUTCOME Trial Results

icoPDF

EMPA-REG OUTCOME Trial Results
Adverse Event Management

icoPDF

Adverse Event Management
Efficacy

icoPDF

Efficacy
Superiority Over SU

icoPDF

Superiority Over SU
Main Benefits

icoPDF

Main Benefits
Dosing

icoPDF

Dosing
EMPA-REG OUTCOME Study Design

icoPDF

EMPA-REG OUTCOME Study Design
How does Nintedanib benefit patients in preserving lung function?

icoPDF

How does Nintedanib benefit patients in preserving lung function?
How does dosing and administration of Nintedanib help compliance of IPF patients?

icoPDF

How does dosing and administration of Nintedanib help compliance of IPF patients?
Is honeycombing in an HRCT, the sole detector of IPF?

icoPDF

Is honeycombing in an HRCT, the sole detector of IPF?
Jardiance vs GLP-1

icoPDF

Jardiance vs GLP-1
Jardiance vs GLP-1

icoPDF

EMPEROR Reduced results
Jardiance vs GLP-1

icoPDF

EMPEROR Reduced Renal Outcome
Jardiance vs GLP-1

icoPDF

Jardiance Efficacy
Jardiance vs GLP-1

icoPDF

Jardiance Safety
Jardiance vs GLP-1

icoPDF

Jardiance Dosing
Load more